CompletedPhase 2NCT01262352

Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation

Studying Congenital pulmonary airway malformation

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Vertex Pharmaceuticals Incorporated
Principal Investigator
Jane Davies
Royal Brompton Hospital and Imperial College
Intervention
Ivacaftor(drug)
Enrollment
21 enrolled
Eligibility
6 years · All sexes
Timeline
20112011

Study locations (8)

Collaborators

Cystic Fibrosis Foundation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01262352 on ClinicalTrials.gov

Other trials for Congenital pulmonary airway malformation

Additional recruiting or active studies for the same condition.

See all trials for Congenital pulmonary airway malformation

← Back to all trials